KEY TAKEAWAYS
- The study aimed to investigate the cardiovascular AE’s risk associated with AA and ENZ treatments in patients with PC.
- Researchers noticed comparable cardiovascular risk between AA and ENZ treatments in PC.
There is growing concern about the adverse metabolic and cardiovascular effects of abiraterone acetate (AA) and enzalutamide (ENZ), two standard hormonal therapies for prostate cancer (PC).
Onur Baser and the team aimed to analyze the risk of cardiovascular adverse events (AE’s) among patients treated with AA and ENZ.
Researchers performed an inclusive analysis utilizing Kythera Medicare data from January 2019 to June 2023 to identify patients with at least 1 pharmacy claim for AA or ENZ. The index date was the first prescription claim date. Patients were required to have 1 year of data pre- and post-index date.
New users excluded those with prior AA or ENZ claims and pre-existing cardiovascular comorbidities. Demographic and clinical variables were analyzed, including age, socioeconomic status (SES), comorbidity score, prostate-specific comorbidities, and healthcare costs. Propensity score matching was employed for risk adjustment.
About 8,929 patients in the AA cohort and 8,624 in the ENZ cohort were initially identified. After adjusting for age, sociodemographic, and clinical factors, 7,647 patients were matched. The matched cohorts (15.54% vs. 14.83%, P < 0.05) showed no statistically significant differences in any cardiovascular event after adjusting for these factors.
The most common cardiovascular event in both cohorts was heart failure (5.20% vs. 4.49%), followed by atrial fibrillation (4.42% vs. 3.60%) and hypotension (2.93% vs. 2.48%).
The study concluded that after adjusting for age, baseline comorbidities, and socioeconomic status (SES), there was no significant difference in the likelihood of experiencing a cardiovascular event between patients treated with AA and those treated with ENZ.
This real-world evidence suggested comparable cardiovascular risk profiles for both treatments, highlighting the importance of considering such risks in PC management.
No funding-related information was available.
Source: https://pubmed.ncbi.nlm.nih.gov/38591349/
Baser O, Samayoa G, Dwivedi A, et al. (2024). “Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.” Acta Oncol. 2024 Apr 9;63:137-146. doi: 10.2340/1651-226X.2024.20337. PMID: 38591349.
